Releases - Biotage

View:

2008

 

Found press releases

 

Resolutions at the Extraordinary General Meeting in Biotage AB on November 21, 2...

11/21/2008 4:35 AM EST
At the Extraordinary General Meeting held in Biotage AB (Reg. No. 556539-3138) on November 21, 2008, the following resolution was passed.

Resolution on reduction of statutory reserve
The General Meeting resolved to reduce the company’s statutory reserve with an amount of SEK 842.180.000 by means of transfer of the aforesaid amount to a reserve to be used in accordance with resolution/s adopted at forthcoming...

NOTICE OF EXTRAORDINARY GENERAL MEETING IN BIOTAGE AB

11/6/2008 3:30 AM EST
Shareholders in Biotage AB are hereby invited to attend the Extraordinary General Meeting, to be held on Friday, November 21, 2008, at 10.00 a.m., at the head office of Biotage AB, Kungsgatan 76 in Uppsala, Sweden.

Notice etc.
Shareholders who wish to participate in the Extraordinary General Meeting must
a) be recorded as a shareholder in the share register maintained by VPC on Friday, November 14, 2008, and...

Biotage AB Nomination Committee

10/17/2008 7:44 AM EST
A Nomination Committee consisting of shareholder representatives and the Chairman of the Board of Directors has been formed for Biotage AB. The Nomination Committee shall, before the Annual General Meeting 2009, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, the determination of fees and matters pertaining thereto.
...

Biotage Divests Biosystems Division to QIAGEN

10/1/2008 2:20 AM EST
As a result of the Strategic Review of Biotage’s entire operations, launched in October 2007, the Board of Biotage AB (“Biotage”) has concluded to divest the Biosystems division (“Biosystems”) and the shares in Corbett Life Science Pty Ltd (“Corbett”) to QIAGEN. The transaction is expected to close on October 2, 2008. Biotage will focus its future activities on the Discovery Chemistry division with attention to...

Interim report January - June 2008

8/15/2008 2:20 AM EST
• Net sales in the second quarter amounted to 121.3 MSEK (131.1) and to 235.3 MSEK (250.0) in the period January – June 2008. At comparable exchange rates net sales were unchanged in the second quarter and increased by 1 percent in the first six months.

• The operating result for the second quarter amounted to 8.9 MSEK (11.1). The operating result for the first six months 2008 amounted to 17.8 MSEK (18.3).

•...

Resolutions at the Annual General Meeting in Biotage AB on April 29, 2008

4/30/2008 3:59 AM EST
At the Annual General Meeting held in Biotage AB (Reg. No. 556539-3138) on April 29, 2008, the following resolutions were passed, among others.

Appropriation of the company’s result
The General Meeting resolved that the company’s accumulated losses amounting to 667,6 MSEK shall be covered by reducing the statutory reserve with the equivalent amount.

Board of Directors etc.
The General Meeting resolved to...

Interim report January – March 2008

4/29/2008 1:54 AM EST
•Net sales amounted to 114,0 MSEK (118,9 MSEK the previous year). At comparable exchange rates net sales increased by 2 percent.

•Biotage’s operating result increased by 23 percent and amounted to 8.9 MSEK (7.2) and the operating margin amounted to 7.8 percent (6.1).

•The result after tax increased by 83 percent to 13.2 MSEK (7.2).

•The cash flow from operating activities amounted to 15.4 MSEK...

The Dept of Pathology at the Uppsala University Hospital evaluates Biotage’s new...

4/1/2008 3:17 AM EST
PyroMarkTMQ24 is the new Biotage Pyrosequencing® platform, which is being launched in March. The Molecular Pathology at the Dept of Pathology, Uppsala University Hospital, is evaluating the new PyroMark Q24TM to implement the Pyrosequencing® technology in cancer diagnostics.

Several novel drugs against the growth hormone receptor EGFR have been recently approved for the treatment of advanced colorectal- and lung...

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB

3/31/2008 2:00 AM EST
Shareholders in Biotage AB are hereby invited to attend the Annual General Meeting, to be held on Tuesday, April 29, 2008, at 4.00 p.m., at the head office of Biotage AB, Kungsgatan 76 in Uppsala, Sweden.

Notice etc.

Shareholders who wish to participate in the General Meeting must
a) be recorded as a shareholder in the share register maintained by VPC on Wednesday, April 23, 2008, and
b) notify the...

Biotage AB and McMaster University sign two year extension to Molecular Imaging ...

3/4/2008 3:21 AM EST
McMaster University has successfully completed the first year research agreement, with a key journal publication and several technical presentations. “We used the Biotage Initiator™ Microwave synthesis system, chromatography cartridges to prepare a range of Carborane Cage structures labeled with rhenium and technetium (Tc99c), the currently most used radionuclide in diagnostic medicine. We reported an 85% reduction...

Biotage

Biotage accelerates the drug discovery and development process and increases the knowledge of the importance of the genetic make-up by providing complete solutions for medicinal chemistry research and applied genetic ana...

View more


  CONTACT